Daniel S. Lorrain, Chief Scientific Officer: Contineum Therapeutics CTNM Sell · Filed 03/02

Trade details

Type: Insider sale
Amount: $62,591.7
Shares · price: 4,170 sh · $15.01 a share
Held after: 151,882 sh
Stock: Contineum Therapeutics CTNM
Person: Daniel S. LorrainChief Scientific Officer
Trade date: 26/03/02
Filed: 26/03/02
Days to filing: 0 days

Sold 2.7% of holdings

Share of holding sold: 2.7%

Contineum Therapeutics trades, last 26 weeks

What else happened in Contineum Therapeutics around then

Filed or reported within 30 days of the trade day · 01/31~04/01

Daniel S. Lorrain's recent trades

Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$154.6K
9,520 sh
$154.6K
Filed 09/01
Traded 09/01
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$147.5K
9,520 sh
$147.5K
Filed 08/03
Traded 08/03
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$156K
9,520 sh
$156K
Filed 07/01
Traded 07/01
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$432.4K
28,826 sh
$432.4K
Filed 06/30
Traded 06/30
Daniel S. LorrainChief Scientific Officer
Sell10b5-1 planContineum Therapeutics
Sell10b5-1 plan
Contineum Therapeutics
CTNM
$54.9K
4,170 sh
$54.9K
Filed 06/01
Traded 06/01